Article info
PDFResearch ethics
Paper
Ethics and eplerenone
- Correspondence to Dr Anthony Scialli, Tetra Tech Sciences, 2200 Wilson Blvd, Suite 400, Arlington, VA 22201, USA; Tony.Scialli{at}tetratech.com
Citation
Ethics and eplerenone
Publication history
- Received September 22, 2011
- Revised August 25, 2012
- Accepted August 29, 2012
- First published September 26, 2012.
Online issue publication
April 27, 2016
Article Versions
- Previous version (27 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Other content recommended for you
- Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms
- The renin-angiotensin-aldosterone system in heart failure for the non-specialist: the past, the present and the future
- Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment
- Aldosterone antagonists improve ejection fraction and functional capacity independently of functional class: a meta-analysis of randomised controlled trials
- Long-term effect of cardiac resynchronisation in patients reporting mild symptoms of heart failure: a report from the CARE-HF study
- An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF)
- Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure
- Development of an economic model to assess the cost-effectiveness of hawthorn extract as an adjunct treatment for heart failure in Australia
- Is there benefit in implanting defibrillators in patients with severe heart failure?
- Added value of a physician-and-nurse-directed heart failure clinic: results from the Deventer–Alkmaar heart failure study